ABBVie , today announced extended long-term data from the Phase 3 RESONATE-2 study evaluating single-agent IMBRUVICA versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma . 1 These data will be presented on June 4 th during the 2021 American Society of Clinical Oncology Annual Meeting . Additionally, new data will be presented during the .
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) today announced the publication of a new resource to help employers make the best decisions.
PHILADELPHIA – Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research , a journal of the American Association for Cancer Research.
Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
A strong start for PEPAXTO in the US
News provided by
Share this article
Share this article
STOCKHOLM, May 26, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the first quarter 2021. Oncopeptides now stands proudly among the few companies that have successfully navigated the long and difficult path from discovery to commercialization says CEO, Marty J Duvall.
Financial overview January-March
Operating loss amounted to SEK 347.3 M (loss: 296.9)